Orphalan has acquired Orphelia Pharma, a company committed to treating rare and severe paediatric diseases, notably in neurology and oncology. The transaction strengthens Orphalan's position as a European leader with a global commercial footprint in rare diseases, expanding its therapeutic portfolio.

The acquisition significantly enhances Orphalan’s capabilities in rare neurological and oncological paediatric diseases, while expanding its global reach to improve access to essential medicines for both children and adults living with rare conditions. The combined entity brings together complementary scientific expertise, operational agility and robust commercial strength, creating a unique platform to accelerate innovation. As the companies move forward together, they remain committed to ensuring continuity of care and strengthening support for partners and patients worldwide.

Speaking in this regard, Dr Naseem Amin, Chief Executive Officer, Orphalan said, "The acquisition of Orphelia Pharma reinforces our mission: to provide innovative and accessible treatments to patients living with rare diseases, wherever they are. 

"Together, we are building a unique platform that brings together scientific excellence, agility, international development and commercial capabilities to advance care for patients of all ages suffering from orphan diseases," he added.

Adding to it, Dr Hugues Bienaymé, Founder and Deputy Chief Executive Officer, Orphelia Pharma, said, "At Orphelia Pharma, we have dedicated ourselves to developing safe and effective pediatric medicines that address major unmet medical needs in rare diseases. Joining Orphalan will allow us to increase the impact of our treatments and make them available more rapidly to the children who need them most."

Gilles Alberici, Chief Executive Officer, Orphelia Pharma, commented, "Bringing together our two complementary companies marks an important milestone, both for our organisations and for the broader community of patients living with rare diseases."